Nuvectis Pharma insider increases stake; post-trade total 3,136,576

Rhea-AI Filing Summary

Nuvectis Pharma (NVCT) reported insider purchases by director Charles Mosseri‑Marlio. He indirectly acquired common stock across three open‑market transactions: 46,900 shares at $6.06 on October 23, 35,034 shares at $6.15 on October 24, and 72,836 shares at $6.28 on October 27.

Following these trades, he beneficially owned 3,136,576 shares, held indirectly through Emerald Hill Ventures SARL SPF, of which he is the beneficial owner.

Insider Trade Summary

Net Buyer: 154,770 shares ($957,083)

Net Buy 4 txns

Insider Mosseri Marlio Charles

Role 10% Owner

Bought 154,770 shs ($957K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	72,836	$6.28	$457K
Purchase	Common Stock	35,034	$6.15	$215K
Purchase	Common Stock	46,900	$6.06	$284K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,136,576 shares (Indirect, By Emerald Hill Ventures SARL SPF.); Common Stock — 109,321 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mosseri Marlio Charles

(Last) (First) (Middle)

27 RIPPLEVALE GROVE

(Street)

LONDON N1 1HS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/23/2025		P		46,900	A	$6.06	3,028,706(1)	I	By Emerald Hill Ventures SARL SPF.
Common Stock	10/24/2025		P		35,034	A	$6.15	3,063,740(1)	I	By Emerald Hill Ventures SARL SPF.
Common Stock	10/27/2025		P		72,836	A	$6.28	3,136,576(1)	I	By Emerald Hill Ventures SARL SPF.
Common Stock								109,321	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL SPF.

	/s/ Charles Mosseri-Marlio	10/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for NVCT?

Charles Mosseri‑Marlio reported open‑market purchases of 46,900 shares at $6.06, 35,034 shares at $6.15, and 72,836 shares at $6.28.

What is the insider’s ownership in NVCT after the reported trades?

Beneficial ownership was 3,136,576 shares following the reported transactions.

Are the NVCT shares held directly or indirectly by the reporting person?

The shares are held indirectly through Emerald Hill Ventures SARL SPF.

What is the insider’s relationship to NVCT?

He is listed as a Director.

On what dates did the NVCT trades occur?

The trades took place on October 23, 2025, October 24, 2025, and October 27, 2025.

What were the reported purchase prices for the NVCT trades?

Reported purchase prices were $6.06, $6.15, and $6.28 per share.